Audentes Therapeutics (BOLD) Coverage Initiated by Analysts at Mizuho

Mizuho started coverage on shares of Audentes Therapeutics (NASDAQ:BOLD) in a report released on Monday, Marketbeat.com reports. The brokerage issued a neutral rating and a $26.00 price target on the biotechnology company’s stock.

Several other research analysts also recently issued reports on the stock. Wedbush raised their price objective on shares of Audentes Therapeutics to $56.00 and gave the stock an outperform rating in a research report on Thursday, January 4th. Zacks Investment Research downgraded shares of Audentes Therapeutics from a hold rating to a sell rating in a research report on Friday, November 17th. BidaskClub downgraded shares of Audentes Therapeutics from a strong-buy rating to a buy rating in a research report on Wednesday, December 6th. Leerink Swann reissued an outperform rating and set a $29.00 price objective (up from $22.00) on shares of Audentes Therapeutics in a research report on Wednesday, November 15th. Finally, HC Wainwright set a $37.00 target price on shares of Audentes Therapeutics and gave the company a buy rating in a report on Thursday, January 4th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Audentes Therapeutics presently has a consensus rating of Buy and a consensus target price of $34.00.

Shares of Audentes Therapeutics (NASDAQ BOLD) traded up $1.47 during trading on Monday, reaching $34.29. 203,100 shares of the company’s stock traded hands, compared to its average volume of 538,700. Audentes Therapeutics has a 52 week low of $13.90 and a 52 week high of $41.80.

In other news, Director Louis G. Lange sold 18,000 shares of Audentes Therapeutics stock in a transaction dated Friday, December 22nd. The shares were sold at an average price of $30.88, for a total value of $555,840.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Suyash Prasad sold 8,000 shares of Audentes Therapeutics stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $28.53, for a total transaction of $228,240.00. The disclosure for this sale can be found here. 47.30% of the stock is owned by insiders.

Large investors have recently modified their holdings of the company. SG Americas Securities LLC purchased a new stake in shares of Audentes Therapeutics in the third quarter valued at about $143,000. Teacher Retirement System of Texas purchased a new stake in Audentes Therapeutics during the fourth quarter worth about $208,000. MetLife Investment Advisors LLC purchased a new stake in Audentes Therapeutics during the fourth quarter worth about $248,000. Nationwide Fund Advisors boosted its holdings in Audentes Therapeutics by 288.9% during the second quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock worth $164,000 after buying an additional 6,384 shares in the last quarter. Finally, Trexquant Investment LP purchased a new stake in Audentes Therapeutics during the third quarter worth about $295,000. 64.94% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This news story was first published by BBNS and is the property of of BBNS. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://baseballnewssource.com/markets/audentes-therapeutics-bold-coverage-initiated-by-analysts-at-mizuho/1885975.html.

About Audentes Therapeutics

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Giants Will Retire No. 25 of Barry Bonds in August
Giants Will Retire No. 25 of Barry Bonds in August


Leave a Reply

 
© 2006-2018 BBNS.